AstraZeneca advances tralokinumab to Phase III in severe asthma
AstraZeneca today announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm.
Results from Phase III programme of lesinurad in combination with xanthine oxidase inhibitors
AstraZeneca announces top-line results from the Phase III programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients.
AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology clinical study
AstraZeneca today announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.
AstraZeneca agrees strategic transaction with Almirall in respiratory disease
Business combination will provide boost to revenue as well as creating long-term value, strengthening AstraZeneca’s respiratory franchise with a complementary pipeline and inhaled device capabilities in asthma and COPD.
AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291
AstraZeneca today announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small-cell lung cancer (NSCLC).
AstraZeneca & QIAGEN enter collaboration to develop diagnostic test for lung cancer patients
AstraZeneca today announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA®.
Seven pharma companies offer up compounds to UK researchers
UK researchers will be granted access to a ‘virtual library’ of deprioritised pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies, announced today by Business Secretary Vince Cable.
MedImmune and Advaxis partner on immuno-oncology combination clinical trial
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.
AstraZeneca reveals designs for new global R&D centre and corporate headquarters in Cambridge
AstraZeneca today revealed the proposed designs for its new global R&D centre and corporate headquarters in Cambridge. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre[1].
AstraZeneca and Max Planck Institute announce research agreement
AstraZeneca today announced an agreement with the Max Planck Institute of Molecular Physiology (MPI), Germany, to establish a ‘satellite unit’ in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.
FDA Advisory Committee votes on accelerated approval for investigational medicine olaparib
AstraZeneca yesterday (Weds) announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have the germline BRCA (gBRCA) mutation, and who are in…
ADDC & AstraZeneca to foster novel drug development among academic research community
The Academic Drug Discovery Consortium (ADDC) announced yesterday (Tuesday) a collaboration between ADDC and AstraZeneca, aimed at facilitating efforts by researchers from academia and institutions towards the discovery of novel compounds with potential pharmaceutical application.
US FDA Advisory Committee recommends no cardiovascular outcomes trial for certain drugs
US FDA Advisory Committee recommends no cardiovascular outcomes trial for peripherally-acting mu-opioid receptor antagonist (PAMORA) class including MOVANTIK(TM).
Brodalumab treatment improved clinical signs and symptoms in arthritis study
Phase II psoriatic arthritis study published in the New England Journal of Medicine.
AstraZeneca in-licenses Synairgen SNG001 as therapy for viral-induced exacerbation in asthma
Phase IIa clinical study to commence in patients with severe asthma.
AstraZeneca to present new data at the American Diabetes Association scientific sessions
AstraZeneca today announced that 43 abstracts reporting results of the company’s research and development in diabetes have been accepted for presentation at the 74th Scientific Sessions® of the American Diabetes Association (ADA) in San Francisco, 13-17 June 2014.
Nobel Laureate Tim Hunt visits China for the Nobel Prize Inspiration Initiative
A lecture series, in partnership with AstraZeneca, aims to inspire young scientists in Shanghai and Chengdu.
AstraZeneca’s novel antibiotic candidate given Fast Track status by US FDA
AstraZeneca today announced that the US Food and Drug Administration (FDA) has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product (QIDP) and awarded its development programme Fast Track status for the treatment of uncomplicated gonorrhoea, which is increasingly resistant to existing antibiotics and poses a serious global public health threat.
AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors on 2 May 2014, as compelling data from over 40 scientific abstracts related to AstraZeneca and MedImmune investigational medicines were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Positive data released on medicine combination for treatment of ovarian cancer
As part of the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), Dr Joyce Liu (on 31 May 2014) presented data on a Phase II study conducted by the American National Cancer Institute (NCI), comparing the efficacy and tolerability of olaparib and cediranib in combination to olaparib alone, for the treatment of women with recurrent platinum-sensitive high-grade serous ovarian…
AstraZeneca and MRC Laboratory of Molecular Biology to launch joint research fund
AstraZeneca today announced its intention to collaborate with the Medical Research Council Laboratory of Molecular Biology (MRC LMB) to fund a range of pre-clinical research projects aimed at better understanding the biology of disease.
AstraZeneca and Tianjin Medical University sign cardiovascular research collaboration
AstraZeneca today announced the signing of a research collaboration in the area of cardiovascular diseases (CVDs) with Tianjin Medical University (TMU), one of China’s leading medical and scientific institutions.
AstraZeneca to demonstrate strength of its oncology pipeline at ASCO
New data from AstraZeneca’s investigational cancer medicines demonstrate the rapid progression of its oncology pipeline. Over 40 scientific abstracts from AstraZeneca and its global biologics R&D arm MedImmune will be featured at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) at the end of this month.
AstraZeneca to present respiratory data at ATS 2014 International Conference
Benralizumab and tralokinumab data both show improvement in key measures of asthma control for patients with specific, severe forms of asthma.
Key MedImmune molecules meet primary endpoints in Phase II studies
AstraZeneca announced that two key molecules in MedImmune’s Respiratory, Inflammation and Autoimmune (RIA) portfolio – mavrilimumab and sifalimumab – met their primary endpoints in respective Phase II studies, demonstrating further pipeline progress in core therapeutic areas.